Trials / Completed
CompletedNCT06258174
A Study of Two Different Formulations of Pirtobrutinib (LOXO-305) In Healthy Participants
A Phase I, Open-Label, Randomized, 2-Way Crossover Study to Compare the PK of Pirtobrutinib (LOXO-305) Tablets
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 28 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The main purpose of this study is to compare two different formulations (mixtures) of pirtobrutinib (LOXO-305) in healthy participants. This study will compare how much of each formulation gets into the blood stream and how long it takes the body to remove it. Information about any side effects that may occur will be collected. The study will last up to 65 days.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pirtobrutinib | Administered orally. |
Timeline
- Start date
- 2021-09-28
- Primary completion
- 2021-12-22
- Completion
- 2021-12-22
- First posted
- 2024-02-14
- Last updated
- 2025-01-13
- Results posted
- 2025-01-13
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT06258174. Inclusion in this directory is not an endorsement.